Results 101 to 110 of about 29,283 (148)

Profiling the Tox21 Compound Library for Their Inhibitory Effects on Cytochrome P450 Enzymes. [PDF]

Int J Mol Sci
Sakamuru S, Travers J, Klumpp-Thomas C, Huang R, Witt KL, Ferguson SS, Simmons SO, Reif DM, Simeonov A, Xia M.   +9 more
europepmc   +1 more source

Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy. [PDF]

Open Heart
Scholtz S, Coppée C, Mohemed K, Potratz M, Sequeira V, Rudolph V, Scholtz W, Reil JC.   +7 more
europepmc   +1 more source

Frequency and Implications of High-Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort. [PDF]

Clin Transl Sci
Moore C, Halman A, Stenta T, Khatri D, Williams E, Dyas R, Stolper J, Elliott DA, Conyers R.   +8 more
europepmc   +1 more source

A Phenotyping Tool for Seven Cytochrome P450 Enzymes and Two Transporters: Application to Examine the Effects of Clopidogrel and Gemfibrozil. [PDF]

Clin Pharmacol Ther
Aurinsalo L, Lapatto-Reiniluoto O, Kurkela M, Neuvonen M, Kiiski JI, Niemi M, Tornio A, Backman JT.   +7 more
europepmc   +1 more source

Evaluation of pharmacogenomic testing to identify cytochrome P450 and SLCO1B1 enzymes and adverse drug events: A non-experimental observational research. [PDF]

Medicine (Baltimore)
Flowers-Moore T, Rapp AR, Salazar JH, Rajendran R.   +3 more
europepmc   +1 more source

Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study. [PDF]

Clin Transl Sci
Conyers R, Stenta T, Somogyi AA, Kirkpatrick C, Halman A, Wang S, Moore C, Khatri D, Williams E, Dyas R, Spelman T, Elliott DA, Gwee A, Alexander M.   +13 more
europepmc   +1 more source

The Prevalence of CYP2C19 Polymorphism in Patients with Symptomatic Intracranial Atherosclerosis. [PDF]

Cerebrovasc Dis Extra
Kittipanprayoon S, Vorasayan P, Chutinet A, Chariyavilaskul P, Suwanwela NC.   +4 more
europepmc   +1 more source

Predictive Biomarkers and Personalized Therapy: Use of Pharmacogenetic Testing in a Scandinavian Perspective. [PDF]

Basic Clin Pharmacol Toxicol
Westergaard N, Lund TM, Vermehren C.
europepmc   +1 more source

Molecular Ancestry Across Allelic Variants of <i>SLC22A1</i>, <i>SLC22A2</i>, <i>SLC22A3</i>, <i>ABCB1</i>, <i>CYP2C8</i>, <i>CYP2C9</i>, and <i>CYP2C19</i> in Mexican-Mestizo DMT2 Patients. [PDF]

Biomedicines
Ortega-Ayala A, de la Cruz CG, Dorado P, Rodrigues-Soares F, Castillo-Nájera F, LLerena A, Molina-Guarneros J.   +6 more
europepmc   +1 more source

Protocol for an observational study to assess the impact of pharmacogenetics on outcomes in vascular surgery (PROSPER). [PDF]

BMJ Open
Burke KA, Mirza S, Wright S, Greaves NS, Newman WG, McDermott JH.   +5 more
europepmc   +1 more source